Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Shield Therapeutics ( (GB:STX) ) has provided an announcement.
Shield Therapeutics reported unaudited 2025 revenues of about $50 million, driven largely by a 56% surge in U.S. ACCRUFeR sales to roughly $46 million, underpinned by a 21% increase in average net selling price and a 33% rise in total prescriptions to about 199,000. The company achieved positive operating cash flow in the fourth quarter, ended 2025 with $11.6 million in cash and cash equivalents, and, supported by record quarterly prescription volumes and improved balance sheet strength, now anticipates delivering an operating profit in 2026, signaling a transition toward sustainable, self-funded growth and a stronger competitive position in the iron deficiency treatment market.
The most recent analyst rating on (GB:STX) stock is a Hold with a £12.00 price target. To see the full list of analyst forecasts on Shield Therapeutics stock, see the GB:STX Stock Forecast page.
Spark’s Take on GB:STX Stock
According to Spark, TipRanks’ AI Analyst, GB:STX is a Neutral.
The overall stock score is primarily influenced by the company’s robust technical momentum and positive corporate events, which are offset by significant financial challenges and valuation concerns. The strong technical indicators and strategic corporate developments provide optimism, but financial instability remains a critical risk.
To see Spark’s full report on GB:STX stock, click here.
More about Shield Therapeutics
Shield Therapeutics is a commercial-stage specialty pharmaceutical company focused on treating iron deficiency and iron deficiency anemia with its flagship oral iron therapy ACCRUFeR/FeRACCRU (ferric maltol). The drug is the first and only FDA-approved oral iron for ID/IDA in the U.S., where Shield is pursuing a $2.3 billion market opportunity, and it is commercialized via an exclusive U.S. collaboration with Viatris and multiple licensing partners across Europe, Asia-Pacific and other key international markets, with patent protection extending into the mid‑2030s.
Average Trading Volume: 2,992,083
Technical Sentiment Signal: Hold
Current Market Cap: £119.5M
See more insights into STX stock on TipRanks’ Stock Analysis page.